This is all in the public domain but my understanding is:
They are awaiting a decision from the Swedish regulator on approval of the estradiol spray Ellavie They are awaiting a decision from the US patent office on the grant of the additional Axiron patent that would extend protection out to 2026 There is no further update yet on the FDA review of the animal health product beyond the announcement on 13 January They are still considering different options for the development of the testosterone spray for women, Luramist The royalty is a percentage of sales (not a percentage of profit) The remaining 195m milestone payments are split into a number of payments (i.e. not just one). All are related to the sales performance of Axiron. Lilly reports its results quarterly and includes detail on sales of its major products. Prior to Axiron becoming one of those products, they haven?t yet determined and agreed with Lilly the appropriate level of disclosure on sales. At this stage all they have decided on future dividends is that they intend to pay regular dividends and expect them to be fully franked.
Cheers
ACR Price at posting:
$3.33 Sentiment: Hold Disclosure: Held
